Hangzhou Women's Hospital
Hangzhou, Zhejiang, 310030, China
NCT Number: NCT04060056
The Westlake Precision Birth Cohort (WeBirth) is a prospective cohort study among women with hyperglycemia during pregnancy and their offspring living in Hangzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with gestational diabetes mellitus (GDM) over 2 weeks, and to facilitate the development of personalized nutritional/lifestyle recommendation among these patients. Another aim of WeBirth is to investigate the association of dietary intake and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the participants with long-term metabolic health of these women and their offspring.
This study is active but is not currently recruiting participants.
18 year and older
Female
Interventional
Not applicable
Hangzhou, Zhejiang, 310030, China
In China, an alarming increase in the prevalence of GDM has been observed in the past decade. GDM is of concern because it is associated with several maternal and fetal medical disorders. Lifestyle changes such as diet and physical activity modifications are key for the prevention and treatment of GDM. However, the associations between dietary intake and physical activity and health outcomes for GDM women and their children remain unclear due to subjective measurements of diet and physical activity. Recently, the development of objective measurements such as food image identification and wearable activity trackers give an opportunity to gain more precise insight into these associations. In addition, for the same food and physical activity exposures, GDM women may have different blood glucose responses, but the nature of variation is currently poorly characterized. Therefore, the present WeBirth design incorporates three unique components, 1) objective measurement of physical activity during pregnancy using accelerometer; 2) measurement of dietary intake using both the Food Frequency Questionnaire and dietary records; 3) measurement of blood glucose levels over 2 weeks using continuous glucose monitors, with three standardized test meals during the 2 weeks. We will then follow up these women participants during and after this pregnancy, and also follow up their offspring.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
● Women with cancer and other serious medical disorders
Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.
Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.
Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
Time frame: Two weeks after enrollment
Glucose levels are assessed by continuous glucose monitoring over 2 weeks.
Time frame: 9-12 weeks after enrollment
Number of participants with adverse birth outcomes, such as, preterm birth, macrosomia and neonatal hypoglycemia.
Time frame: 6 months and 3 years after delivery
Body fat is assessed by the equipment of dual-emission X-ray absorptiometry (DXA) for the mothers.
Time frame: at delivery, age of 6 months, 1 year, 3 years and 6 years
Weight in kilograms
Time frame: 6 years and 10 years after delivery
Risk of developing type 2 diabetes after the delivery of the women with gestational diabetes.
Westlake University
Other
Acronym: WeBirth
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06291766
Blood Glucose Self Monitoring, Diabetes Mellitus
Lund, Sweden
View Trial DetailsNCT03029702
Diabetes Mellitus, Diabetes, Gestational
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT04542148
Diabetes Mellitus, Diabetes Mellitus, Type 2
Birmingham, Alabama, United States
View Trial DetailsNCT03681054
Birth Weight, Body Composition
Helsinki, Finland
View Trial Details